NanoTherapX: Revolutionizing Dermatology with Nanomedicine
Discover NanoTherapX, a leading nanomedicine startup transforming dermatology with advanced nanotechnology for chronic skin conditions.
LazyFounders
NanoTherapX: Revolutionizing Dermatology with Nanomedicine
30 SEC SUMMARY
NanoTherapX, an IIT Bombay-incubated startup, is pioneering next-generation nanomedicine solutions for dermatology, offering targeted, plant-based therapies for chronic skin conditions with fewer side effects. Their flagship product, PsorisCare, is a patented nanotherapeutic gel for psoriasis management.
TABLE OF CONTENTS
- Introduction
- About NanoTherapX
- Technology and Innovations
- Business Model and Client Segment
- Founding Team
- Awards and Recognition
- Frequently Asked Questions
- Conclusion
- Call-to-Action
KEY HIGHLIGHTS
- NanoTherapX uses advanced nanotechnology for targeted skin therapies.
- PsorisCare is a patented plant-based nanotherapeutic gel for psoriasis.
- The company aims to bridge the gap between lab innovation and accessible healthcare.
- Recognized with Prix Galien India nomination and CAS Future Leaders Top 100.
Introduction
In the rapidly evolving field of healthcare technology, NanoTherapX Innovations Pvt. Ltd. stands out as a beacon of innovation. Founded in 2025, this IIT Bombay-incubated startup is at the forefront of developing next-generation nanomedicine solutions for dermatology and skin health.
About NanoTherapX
NanoTherapX is dedicated to transforming the treatment of chronic skin disorders through scientifically validated, affordable, and patient-friendly therapeutic technologies. Their mission is to set a new standard in personalized skincare by offering deeper relief and fewer side effects compared to conventional treatments.
Technology and Innovations
NanoTherapX's flagship product, PsorisCare, is a patented, plant-based, non-steroidal nanotherapeutic gel designed for the management of psoriasis. The technology utilizes lipid nanoparticle-based delivery systems to enhance skin penetration, provide sustained drug release, and improve therapeutic outcomes while minimizing side effects associated with conventional steroid therapies.
Beyond psoriasis, NanoTherapX is leveraging its proprietary nanotechnology platform to develop innovative solutions for melasma, hair care, and other dermatological conditions.
Business Model and Client Segment
NanoTherapX operates on a B2B model, licensing its patented nanomedicine platforms and dermatology products to pharmaceutical, biotech, dermatology, and cosmeceutical companies. Their client segment includes startups, small, medium, and large enterprises, targeting a global market.
Founding Team
The core team at NanoTherapX comprises experts in nanomedicine, dermatology, business strategy, and finance, including:
- Dr. Roshan Keshari
- Prof. Rohit Srivastava
- Prof. Shamik Sen
Awards and Recognition
The founding team received national and international recognition, including a nomination for the Prix Galien India 2025 and inclusion in the CAS Future Leaders Top 100, validating the innovation and impact of their technology.
Frequently Asked Questions
Where is NanoTherapX Innovations Pvt, Ltd headquartered?
NanoTherapX Innovations Pvt. Ltd. is headquartered in Mumbai, Maharashtra, India.
What is the business model of NanoTherapX Innovations Pvt, Ltd?
NanoTherapX operates on a B2B licensing model, providing patented nanomedicine platforms and dermatology products to pharmaceutical, biotech, and cosmeceutical companies.
What is the founding date of NanoTherapX Innovations Pvt, Ltd?
NanoTherapX Innovations Pvt. Ltd. was incorporated in April 2025.
Conclusion
NanoTherapX is revolutionizing the dermatology sector with its cutting-edge nanomedicine solutions. By bridging the gap between laboratory innovation and accessible healthcare, the company is poised to make a significant clinical, social, and commercial impact globally.
Call-to-Action
Discover more about NanoTherapX and their groundbreaking innovations by visiting blogy.in.
Sources
This story is an original summary and analysis written by LazyFounders from the reporting listed above. Facts are attributed to their original publishers; sections marked as analysis are LazyFounders's opinion. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links.
